Payment overview · 2025
General Payments
$865.01
58 reported records · 10 companies
Healthcare provider profile · identity verified
Darrell G. Ragland, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JONESBORO, AR · NPI 1912960238
Verified facts
What the public records show
CMS Open Payments records show Darrell G. Ragland, M.D. received $865.01 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $209.68 | 24.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $171.09 | 19.8% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $160.97 | 18.6% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.56 | 17.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.34 | 7.1% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.73 | 5.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.22 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.07 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.54 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.81 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $865.01 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.57 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.79 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $122.66 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.66 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $114.49 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $101.80 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.41 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $97.41 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.34 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.34 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.43 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.73 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.28 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $27.18 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 179 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
204 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 959 | 226 |
| Losartan Potassium | Losartan Potassium | 911 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 865 | 210 |
| Alprazolam | Alprazolam | 858 | 138 |
| Metformin Hcl | Metformin Hcl | 662 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 646 | 147 |
| Omeprazole | Omeprazole | 556 | 134 |
| Gabapentin | Gabapentin | 517 | 116 |
| Simvastatin | Simvastatin | 507 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 495 | 134 |
| Potassium Chloride | Potassium Chloride | 487 | 120 |
| Lisinopril | Lisinopril | 475 | 113 |
| Citalopram Hbr | Citalopram Hydrobromide | 455 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 429 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 426 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 96 |
| Tramadol Hcl | Tramadol Hcl | 380 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 354 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 329 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 320 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 313 | 79 |
| Furosemide | Furosemide | 293 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 261 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 231 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 69 |
| Sertraline Hcl | Sertraline Hcl | 218 | 53 |
| Carvedilol | Carvedilol | 217 | 55 |
| Trazodone Hcl | Trazodone Hcl | 205 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 48 |
| Jardiance | Empagliflozin | 204 | 39 |
| Clonazepam | Clonazepam | 194 | 28 |
| Ozempic | Semaglutide | 179 | 30 |
| Eliquis | Apixaban | 163 | 28 |
| Allopurinol | Allopurinol | 145 | 33 |
| Glimepiride | Glimepiride | 142 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 38 |
| Montelukast Sodium | Montelukast Sodium | 136 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 47 |
| Ezetimibe | Ezetimibe | 129 | 32 |
| Diazepam | Diazepam | 127 | 17 |
| Mounjaro | Tirzepatide | 118 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 24 |
| Famotidine | Famotidine | 106 | 27 |
| Farxiga | Dapagliflozin Propanediol | 101 | 22 |
| Spironolactone | Spironolactone | 94 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 86 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 17 |
| Bupropion Xl | Bupropion Hcl | 81 | 22 |
| Lorazepam | Lorazepam | 72 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 71 | 14 |
| Mirtazapine | Mirtazapine | 68 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Ondansetron Odt | Ondansetron | 62 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Pregabalin | Pregabalin | 62 | 14 |
| Amoxicillin | Amoxicillin | 59 | 45 |
| Atenolol | Atenolol | 59 | 13 |
| Cephalexin | Cephalexin | 59 | 48 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | suppressed |
| Meloxicam | Meloxicam | 56 | 18 |
| Prednisone | Prednisone | 55 | 42 |
| Promethazine Hcl | Promethazine Hcl | 54 | 15 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Topiramate | Topiramate | 53 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | 21 |
| Valsartan | Valsartan | 51 | 15 |
| Fenofibrate | Fenofibrate | 49 | 16 |
| Meclizine Hcl | Meclizine Hcl | 45 | 17 |
| Finasteride | Finasteride | 44 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 13 |
| Irbesartan | Irbesartan | 41 | suppressed |
| Estradiol | Estradiol | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 11 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 18 |
| Ramipril | Ramipril | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $865.01 · 58 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error